Psychopharmacology

, Volume 99, Supplement 1, pp S32–S37 | Cite as

Clozapine — pharmacokinetic investigations and biochemical effects in man

  • M. Ackenheil
Article

Abstract

Clozapine with its unique pharmacological profile was investigated in different studies in order to elucidate its clinical-biochemical effects. Acute pharmacokinetic data showed a wide interindividual range with a mean halflife time of 6.0 h. The excretion pattern of catecholamines and their metabolites as well as hormone secretion were influenced in a different way. After 30 days of treatment, psychotic symptoms had markedly improved. However, only weak correlations were found to plasma levels. Side effects, such as sedation and orthostatic dysregulation, adapted and normalized during treatment. CSF-MHPG, CSF-5-HIAA decreased, CSF-HVA increased after 20 days of treatment indicating that the dopamine as well as the serotonin and noradrenaline systems are affected by Clozapine.

Key words

Clozapine plasma levels Pharmacokinetics Catecholamines Hormones Side effects Psychopathology 

References

  1. Anden NE, Stock G (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J Pharm Pharmacol 25:346–348Google Scholar
  2. Anderson GD, Rebec GV (1988) Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biol Psychiatry 23:497–506Google Scholar
  3. Angst J, Battegay R, Bente D, Berner P, Broeren W, Cornu F, Dick P, Engelmeier M, Heimann H, Heinrich K, Helmchen H, Hippius H, Pöldinger W, Schmidlin P, Schmitt E, Weis P (1969) Das Dokumentationssystem der Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatry (AMP). Arzneimittelforschung/Drug Res 19:399–405Google Scholar
  4. Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmakopsychiatrie 4:201–211Google Scholar
  5. Blum A, Mauruschat W (1972) Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika unter besonderer Berücksichtigung des neuartigen Dibenzo-Diazepin-Derivates Clozapin. Pharmakopsychiatrie 5:155–169Google Scholar
  6. Bondesson U, Lindström LH (1988) Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 95:472–475Google Scholar
  7. Brodie BB, Mitchell JR (1973) The value of correlating biological effects of drugs with plasma concentration. In: Davies DS, Prichard BNC (eds) Biological effects of drugs in relation to their plasma concentrations. Proc Br Pharm Soc 1972, Macmillan, London, pp 1–12Google Scholar
  8. Bürki HR, Ruch W, Asper H, Baggiolini M, Stille G (1973) Pharmakologische und neurochemische Wirkungen von Clozapin: neue Gesichtspunkte in der medikamentösen Behandlung der Schizophrenie. Schweiz Med Wochenschr 103:1716–1724Google Scholar
  9. Coward DM (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology [Suppl] 99:S6-S12Google Scholar
  10. Delini-Stula A (1986) Neuroanatomical, neuropharmacological and neurobiochemical target systems for antipsychotic activity of neuroleptics. Pharmacopsychiatry, 19:134–139Google Scholar
  11. Farde L, Wiesel F-A, Nordström A-L, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology [Suppl] 99:S28-S31Google Scholar
  12. Friedman H, Greenblatt DJ (1986) Rational therapeutic drug monitoring. State of the art/review. JAMA 256:2227–2233Google Scholar
  13. Hand TH, Hu X-T, Wang RY (1986) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257–269Google Scholar
  14. Helmchen H, Hippius H, Matussek N, Müller-Oerlinghausen B (1975) Über Blutzellschädigungen durch trizyklische Psychopharmaka. Deutsches Ärzteblatt — Ärztliche Mitteilungen 43:2961–2964Google Scholar
  15. Küfferle B (1976) Zum Spektrum der Nebenwirkungen von Clozapin. In: Berner P, Saletu B (eds) Clozapin, II. Symposium. Wien: Pharmazeutika WanderGoogle Scholar
  16. Laborit H, Hugenard P (1951) L'hibernation artificielle par moyens pharmacodynamiques et physiques. Presse Méd 59:1329Google Scholar
  17. Maj J, Sowinska H, Baran L, Palider E (1974) The central action of clozapine. Pol J Pharmacol 26:425–435Google Scholar
  18. Markianos E, Nyström I (1974) Studie über die Dopamin-β-Hydroxylase im Serum. Arzneimittelforschung/Drug Res 24:1021–1023Google Scholar
  19. Meltzer HY (1988) Human biological studiesGoogle Scholar
  20. Mombour W (1974) Syndrome bei psychiatrischen Erkrankungen. Eine vergleichende Untersuchung mit Hilfe von zwei Schätzskalen für den psychopathologischen Befund (IMPS und AMP-Skalen), Arch Psychiatr Nervenkr 219:331–350Google Scholar
  21. Pickar D, Laborea R, Linoila M, Roy A, Hommer D, Everett D, Paul SM (1984) Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science 225:954–956Google Scholar
  22. Scatton B, Garret C, Julou L (1975) Acute and subacute effects of neuroleptic on dopamine synthesis and release in the rat striatum. NS Arch Pharmacol 289:419–434Google Scholar
  23. Siegenthaler W, Veragut U, Werning G (1973) Blutdruck. In: Siegenthaler W (ed) Klinische Pathophysiologie. Thieme, Stuttgart, pp 575–592Google Scholar
  24. Smith RC, Davis JM (1976) Behavioral evidence for supersensitivity after chronic administration of haloperidol, clozapine, and thioridazine. Life Sci 19:725–732Google Scholar
  25. Strahlendorff B v, Ackenheil M, Zimmermann J (1976) Akute und chronische Wirkung von Carpipramin, Clozapin, Haloperidol und Sulpirid auf den Stoffwechsel biogener Amine im Rattengehirn. Arzneimittelforschung/Drug Res 26:1096–1098Google Scholar
  26. Wilk S, Watson E, Stanley ME (1975) Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine. J Pharmacol Exp Ther 195:265–270Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • M. Ackenheil
    • 1
  1. 1.Psychiatric Department of the Munich UniversityMünchen 2Federal Republic of Germany

Personalised recommendations